# Belinostat in Treating Patients With Myelodysplastic Syndromes

> **NCT00357162** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- de Novo Myelodysplastic Syndromes
- Previously Treated Myelodysplastic Syndromes
- Secondary Myelodysplastic Syndromes

## Interventions

- **DRUG:** belinostat

## Key facts

- **NCT ID:** NCT00357162
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357162, "Belinostat in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00357162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*